Not in San Diego: We took a close look at the potential for targeting gamma delta (𝞬𝝳) T cells early last year in an extended mini-series looking at the landscape including some of the early companies leading the way in this niche.
Since then there’s been a raft of company related announcements and collaborations in recent months, highlighting the ongoing interest in this field.
In this post, it’s time to revisit the original landscape (link), as well as explore how well some of the biotech companies who are active in this space are navigating the R&D roller coaster.
We will also be discussing recent data presented at the AACR20 virtual meetings.
So what did we learn about gamma delta T Cell therapies at AACR20 – who stands out from the increasingly crowded pack?
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the AACR meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
London – last week a half day event at The Francis Crick Institute looked at three UK cell therapy companies that have been spun out of academic research from partner institutions, UCL and King’s College London.
Professor Julian Downward welcomes everyone to The Crick
We heard from the CEOs of Achilles Therapeutics, GammaDelta Therapeutics and Autolus Therapeutics on how they are translating science into new adoptive cellular therapies.
There were also presentations from leading scientists whose research they are commercializing.
All three companies were founded in 2016, so the event was a fascinating snapshot as to where are they now, roughly 3 years on, what have they achieved and where are they going.
They vary in terms of their vision, innovation and their adoptive cellular therapy approach.
Autolus are developing autologous CAR-T cell therapies, GammaDelta Therapeutics are focusing on allogeneic Vδ1 gamma delta (ϒδ) T cells, while Achilles Therapeutics are targeting patient-derived clonal neoantigens.
If you couldn’t make this Medicine at the Crick event, what were some of the take home messages, and how do we think these companies compare to some of their competitors?
Subscribers can log-in to read more or you can purchase access to BSB Premium Content.
In the first post in our mini-series about the potential for gamma delta (γδ) T cells in cancer immunotherapy, Prof Adrian Hayday took us on a voyage of discovery through the pioneering research he and colleagues did at MIT, Yale, King’s College London (KCL) and The Francis Crick Institute in London.
Prof Adrian Hayday FRS
Along the way he highlighted how our current understanding of γδ T cells has developed over the last thirty years.
“All truths are easy to understand once they are discovered, the point is to discover them.”
This maxim attributed to Galileo Galilei in a 1632 publication, is very pertinent to Prof Hayday’s research which was a fascinating journey of discovery.
For the second post in our mini-series we have a Q&A with Prof Hayday that takes the story forward and looks at how our understanding of the science behind γδ T cells has opened the door to translational and clinical opportunities such as adoptive cellular therapy.
To learn more from our latest thought leader interview and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.